IBER

Ibere Pharmaceuticals
IBER

Overview Fund Activity
Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

46 hedge funds and large institutions have $103M invested in Ibere Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
46
Holders Change
-2
Holders Change %
-4.17%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
5
Increased
6
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
GCL
Glazer Capital LLC
New York
+$3.25M
2
PAMP
Polar Asset Management Partners
Ontario, Canada
+$1.76M
3
CF
Cantor Fitzgerald
New York
+$1.1M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1M
5
AA
AQR Arbitrage
Connecticut
+$981K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$5.39M
2
SCM
Shaolin Capital Management
Florida
-$1.96M
3
CCM
Context Capital Management
California
-$1.13M
4
ICMH
Integrity Capital Management (HK)
Hong Kong
-$458K
5
DFCM
Dark Forest Capital Management
Puerto Rico
-$224K
Name Holding Trade Value Shares
Change 		Shares
Change %
TIM
51
Timelo Investment Management
Ontario, Canada
– -$146K -14,900 Closed
PCM
52
Prelude Capital Management
New York
– -$98K -10,000 Closed
1 2
3